Matinas BioPharma Holdings Inc Asset Resilience Ratio
Matinas BioPharma Holdings Inc asset resilience ratio. Matinas BioPharma Holdings Inc (MTNB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Matinas BioPharma Holdings Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Matinas BioPharma Holdings Inc (2014–2024)
Asset resilience ratio of Matinas BioPharma Holdings Inc from 2014 to 2024. This chart shows how Matinas BioPharma Holdings Inc's Asset Resilience Ratio has changed over time. Read Matinas BioPharma Holdings Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Matinas BioPharma Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Matinas BioPharma Holdings Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Matinas BioPharma Holdings Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Matinas BioPharma Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Matinas BioPharma Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Matinas BioPharma Holdings Inc Asset Resilience Ratio by Year (2014–2024)
Matinas BioPharma Holdings Inc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Matinas BioPharma Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $12.64 Million | -- |
| 2023-12-31 | 35.73% | $8.97 Million | $25.10 Million | +7.92pp |
| 2022-12-31 | 27.81% | $21.93 Million | $78.87 Million | -18.81pp |
| 2021-12-31 | 46.62% | $28.59 Million | $61.33 Million | -18.54pp |
| 2020-12-31 | 65.17% | $46.25 Million | $70.97 Million | +51.24pp |
| 2019-12-31 | 13.93% | $5.61 Million | $40.24 Million | +12.85pp |
| 2017-12-31 | 1.07% | $155.00K | $14.42 Million | -0.51pp |
| 2016-12-31 | 1.59% | $156.00K | $9.82 Million | +0.40pp |
| 2015-12-31 | 1.19% | $100.00K | $8.41 Million | -1.79pp |
| 2014-12-31 | 2.97% | $100.00K | $3.36 Million | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more